Atlas Trials

Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Clinical trial NCT04066790 · TERMINATED

Trial details

NCT number
NCT04066790
Sponsor
Shanghai Jiao Tong University School of Medicine
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2019-09-09
Primary completion
2020-04-30
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.